{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:48:57Z","timestamp":1767707337107},"reference-count":31,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.jacl.2011.07.003","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T12:52:57Z","timestamp":1311684777000},"page":"121-131","source":"Crossref","is-referenced-by-count":4,"title":["A systematic review on evidence of the effectiveness and\u00a0safety of a wax-matrix niacin formulation"],"prefix":"10.1016","volume":"6","author":[{"given":"Andrew P.","family":"Dunatchik","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew K.","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos A.","family":"Dujovne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2011.07.003_bib1","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/0003-9861(55)90070-9","article-title":"Influence of nicotinic acid on serum cholesterol in man","volume":"54","author":"Altschul","year":"1955","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.jacl.2011.07.003_bib2","series-title":"Adult Treatment Panel III Report. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults","author":"National Cholesterol Education Program","year":"2001"},{"issue":"13 Suppl. 2","key":"10.1016\/j.jacl.2011.07.003_bib3","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/ajhp\/60.suppl_2.S9","article-title":"Overview of niacin formulations: Differences in pharmacokinetics, efficacy, and safety","volume":"60","author":"Pieper","year":"2003","journal-title":"AM J Health-Syst Pharm"},{"issue":"12A","key":"10.1016\/j.jacl.2011.07.003_bib4","first-page":"34L","article-title":"The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol","volume":"86","author":"Piepho","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.07.003_bib5","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/j.1365-2796.1989.tb01393.x","article-title":"Pronounced lowering of serum levels of lipprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid","volume":"226","author":"Carlson","year":"1989","journal-title":"J Intern Med"},{"key":"10.1016\/j.jacl.2011.07.003_bib6","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2011.07.003_bib7","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and Niacin, Antioxidant Vitamins, or the Combination forthe Prevention of Coronary Disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.07.003_bib8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0002-9149(00)01410-7","article-title":"Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia","volume":"87","author":"Wolfe","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2011.07.003_bib9","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2011.07.003_bib10","unstructured":"Thomson Reuters (HealthCare) Inc. Micromedex Healthcare Series. 11 August 2010. Available at: http:\/\/www.thomsonhc.com.liboff.ohsu.edu\/micromedex2\/librarian\/ND_T\/evidencexpert\/ND_PR\/evidencexpert\/CS\/126184\/ND_AppProduct\/evidencexpert\/DUPLICATIONSHIELDSYNC\/88B0A1\/ND_PG\/evidencexpert\/ND_B\/evidencexpert\/ND_P\/evidencexpert\/PFActionId\/evidencexpert.DoI. Accessed July 28, 2011."},{"key":"10.1016\/j.jacl.2011.07.003_bib11","unstructured":"National Institutes of Health. NIH Stops Clinical Trial On Combination Cholesterol Treatment, from National Institutes of Health. NIH stops clinical trial on combination cholesterol treatment. (May, 26 2011). Available at: http:\/\/www.theheart.org\/viewDocument.do?document=http%3A%2F%2Fwww.nih.gov%2Fnews%2Fhealth%2Fmay2011%2Fnhlbi-26.htm. Accessed June 22, 2011."},{"key":"10.1016\/j.jacl.2011.07.003_bib12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1056\/NEJM199908123410707","article-title":"Drug treatment of lipid disorders","volume":"341","author":"Knopp","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2011.07.003_bib13","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.1994.03510330050033","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2011.07.003_bib14","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0026-0495(98)90284-0","article-title":"Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia","volume":"47","author":"Knopp","year":"1998","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2011.07.003_bib15","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.2165\/00003495-200565180-00014","article-title":"Prolonged-release nicotinic acid a review of its use in the treatment of dyslipidaemia","volume":"65","author":"McCormack","year":"2005","journal-title":"Drugs"},{"key":"10.1016\/j.jacl.2011.07.003_bib16","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0026-0495(92)90170-F","article-title":"Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?","volume":"41","author":"Stern","year":"1992","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2011.07.003_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacl.2007.04.003","article-title":"The role of nicotinic acid metabolites in flushing and hepatotoxicity","volume":"1","author":"Stern","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2011.07.003_bib18","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/clpt.1982.63","article-title":"Aspirin blocks nicotinic acid-induced flushing","volume":"31","author":"Wilkin","year":"1982","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacl.2011.07.003_bib19","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.1172\/JCI23626","article-title":"GPR109A (PUMA-G\/HM74A) mediates nicotinic acid-induced flushing","volume":"115","author":"Benyo","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2011.07.003_bib20","doi-asserted-by":"crossref","first-page":"9869","DOI":"10.1074\/jbc.M210695200","article-title":"Molecular identification of high and low affinity receptors for nicotinic acid","volume":"278","author":"Wise","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2011.07.003_bib21","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7326\/0003-4819-139-12-200312160-00009","article-title":"Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia","volume":"139","author":"Meyers","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacl.2011.07.003_bib22","unstructured":"Food and Drug Administration. Fact Sheet: Dietary Supplement Current Good Manufacturing Practices (CGMPs) and Interim Final Rule (IFR) Facts. Available at: http:\/\/www.fda.gov\/Food\/DietarySupplements\/GuidanceComplianceRegulatoryInformation\/RegulationsLaws\/ucm110858.htm. Accessed July 28, 2011."},{"key":"10.1016\/j.jacl.2011.07.003_bib23","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.2146\/ajhp060089","article-title":"Dissolution profiles of nonprescription extended release niacin and insositol niacinate products","volume":"63","author":"Poon","year":"2006","journal-title":"Am J Health-Syst Pharm"},{"key":"10.1016\/j.jacl.2011.07.003_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/0026-0495(85)90092-7","article-title":"Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin","volume":"34","author":"Knopp","year":"1985","journal-title":"Metabolism"},{"key":"10.1016\/j.jacl.2011.07.003_bib25","unstructured":"Endurance Products Company. Endurance Products. Available at: http:\/\/www.endur.com\/index.cfm?fuseaction=shopping.display&subcatid=2&pageid=2&parentid=2&parentpage=0. Accessed July 28, 2011."},{"key":"10.1016\/j.jacl.2011.07.003_bib26","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1001\/archinte.1991.00400070172024","article-title":"Niacin revisited: a randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia","volume":"151","author":"Keenan","year":"1991","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacl.2011.07.003_bib27","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1532-5415.1992.tb01822.x","article-title":"Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin","volume":"40","author":"Keenan","year":"1992","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacl.2011.07.003_bib28","first-page":"313","article-title":"A clinical trial of oat bran and niacin in the treament of hyperlipidemia","volume":"34","author":"Keenan","year":"1992","journal-title":"J Fam Pract"},{"key":"10.1016\/j.jacl.2011.07.003_bib29","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1001\/archfami.5.10.567","article-title":"Clinical trial of wax-matrix sustained-release niacin in a russian population with hypercholesterolemia","volume":"5","author":"Aronov","year":"1996","journal-title":"Arch Fam Med"},{"key":"10.1016\/j.jacl.2011.07.003_bib30","unstructured":"Abbott Pharmaceuticals. Niaspan Package Insert. 1997. Niaspan.com. 27 July 2010. Available at: http:\/\/www.rxabbott.com\/pdf\/niaspan.pdf. Accessed July 28, 2011."},{"key":"10.1016\/j.jacl.2011.07.003_bib31","unstructured":"University of Oxford. THRIVE. 28th July 2010. Available at: http:\/\/www.ctsu.ox.ac.uk\/\u223cthrive\/. Accessed July 28, 2011."}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287411006696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,13]],"date-time":"2019-06-13T10:21:29Z","timestamp":1560421289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287411006696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1933287411006696"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2011.07.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}